In his capacity as CEO of Alligator Bioscience AB, Medicon Valley Alliance, chairman of the Board, Søren Bregenholt was invited to the BioStock studio to elaborate on a recent and very positive update on the ongoing OPTIMIZE-1 clinical Phase Ib/II trial in first-line metastatic pancreatic cancer with the company’s lead asset, mitazalimab and the fact that the company has recently appointed Dr Sumeet Ambarkhane, MD, as its Chief Medical Officer.
See the full interview and read the announcement about mitazalimab on Alligator´s webpage